Dr Anthony Dear - Researcher Profile

Anthony Dear

Address

Eastern Health Clinical School
Level 2

Biography

Dr Dear completed his Medical Degree, with Honours, at Monash University in 1988. He continued his clinical training at the Alfred and Box Hill Hospital campuses and currently holds an appointment at Eastern Health as a clinical consultant in Vascular Medicine. In 1997 he obtained his PhD from Monash University for research examining the molecular biological control of components of the plasminogen activating system.

 

Dr Dear currently holds a Senior Research Fellow appointment at Monash University, Department of Medicine, Eastern Clinical School, and at The Australian Centre for Blood Diseases (ACBD), Department of Medicine, Monash University AMREP facility located at the Alfred Hospital where he heads the Eastern Clinical Research Unit (ECRU) Translational Research Division Laboratory.

 

Dr Dear is involved in several scientific collaborations with National and International research groups, is Deputy Director of the Eastern Clinical Research Unit (ECRU) situated at the Box Hill, Maroondah and Alfred hospitals and principle and co-investigator in numerous International clinical trials in multiple disciplines.

 

Dr Dear’s current scientific interests include the application of a novel class of therapeutics, the Histone Deacetylase Inhibitors (HDACi) to several disease states and delineating previously unrecognised benefits of currently available agents in the treatment of diabetes.

 

Dr Dear is a Medical Associate to Healthscope Molecular Diagnostics and has been instrumental in establishing pharmacogenetic services in relation to anti-coagulation management and the treatment of thrombosis.

 

Dr Dear is a member of the Australian Society of Thrombosis and Haemostasis (ASTH) and the Australian Vascular Biology Society (AVBS)

 

 

Related Links:

Research & Supervision Interests

    The ECRU Translational Research Division laboratory is based at the Australian Centre for Blood Diseases (ACBD), Monash University, 6th Floor, Burnett Tower, AMREP facility, Commercial Rd, Prahran, Melbourne. Within the laboratory I supervise a research team involved in in vitro and in vivo evaluation of novel HDACi’s and a number of other translational research projects. The research team consists of Dr Hong Bin Liu (Post Doctoral Research Fellow), Dr Yushan Hu (Post Doctoral Research Fellow), past and present BSc (Hons) and PhD students including Dr Antony Vinh, Dr Penny Mayes, Ms Fiona Wightman and myself and is funded by Monash University, Eastern Clinical Research Unit, Translational Research  Division through governmental organisations and pharmaceutical company research grants. All facilities required to perform the experiments outlined in the current research program are available from either the ACBD or in the laboratories of our collaborators.

Keywords

Cancer Biology, Cellular Biology, Clinical Trial, Demethylating agents, Diabetes, Epigenetics, Histone Deacetylase Inhibitors, Molecular Biology, Translational research, Vascular Biology, Vascular Disease, glucagon-like, diabetes, endothelial cells

Qualifications

PhD
Institution: Monash University
Year awarded: 1997
M.B, B.S (Hons)
Institution: Monash University
Year awarded: 1988

Publications

Journal Articles

Costa, M., Sourris, K., Lim, S.M., Yu, Q.C., Hirst, C.E., Parkington, H.C., Jameson, V.J., Dear, A.E., Liu, H.B., Micallef, S.J., Koutsis, K., Elefanty, A.G., Stanley, E., 2013, Derivation of endothelial cells from human embryonic stem cells in fully defined medium enables identification of lysophosphatidic acid and platelet activating factor as regulators of eNOS localization, Stem Cell Research [P], vol 10, issue 1, Elsevier BV, The Netherlands, pp. 103-117.

Dick, R.J.L., Byron, K., Dear, A.E., 2012, Clinical-scientific notes, Internal Medicine Journal [P], vol 42, Wiley-Blackwell Publishing Asia, Richmond, VIC 3121 Australia, pp. 7-8.

Gaspari, T., Liu, H., Welungoda, I., Hu, Y., Widdop, R., Knudsen, L., Simpson, R., Dear, A., 2011, A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model, Diabetes and Vascular Disease Research [P], vol 8, issue 2, Sage Publications Ltd, UK, pp. 117-124.

Dick, R., Dear, A., Byron, K., 2011, Clopidogrel Resistance: Case reports of CYP2C19 gene variants in suspected coronary stent thrombosis, Heart Lung and Circulation [P], vol 20, issue 10, Elsevier Australia, Chatswood, NSW 2067 Australia, pp. 657-658.

Hu, Y., Liu, H., Simpson, R., Dear, A., 2011, PPAR(gamma)-independent thiazolidinedione-mediated inhibition of NUR77 expression in vascular endothelial cells, Journal of Endocrinology [P], vol 208, issue 1, BioScientifica Ltd, UK, pp. R1-R7.

Liu, H.B., Mayes, P.A., Perlmutter, P., McKendrick, J., Dear, A.E., 2011, The anti-leukemic effect and molecular mechanisms of novel hydroxamate and benzamide histone deacetylase inhibitors with 5-aza-cytidine, International Journal of Oncology [P], vol 38, issue 5, Spandidos Publications, Greece, pp. 1421-1425.

Ferguson, C.D., Clancy, P., Bourke, B., Walker, P.J., Dear, A., Buckenham, T., Norman, P., Golledge, J., 2010, Association of statin prescription with small abdominal aortic aneurysm progression, American Heart Journal [P], vol 159, issue 2, Mosby, Inc., United States, pp. 307-313.

Krishna, S.M., Dear, A.E., Norman, P., Golledge, J., 2010, Genetic and epigenetic mechanisms and their possible role in abdominal aortic aneurysm, Atherosclerosis [P], vol 212, issue 1, Elsevier Ireland Ltd, Ireland, pp. 16-29.

Liu, H.B., Dear, A.E., Knudsen, L.B., Simpson, R., 2009, A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules, Journal of Endocrinology [P], vol 201, issue 1, Society for Endocrinology, UK, pp. 59-66.

Restall, C., Doherty, J., Liu, H.B., Genovese, R., Paiman, L., Byron, K., Anderson, R., Dear, A.E., 2009, A novel histone deacetylase inhibitor augments tamoxifen-mediated attenuation of breast carcinoma growth, International Journal Of Cancer [P], vol 125, issue 2, John Wiley & Sons, Inc., USA, Switzerland, Germany, pp. 483-487.

Liu, H.B., VOSO, M.T., Gumiero, D., Duong, J., mckendrick, J., Dear, A.E., 2009, The anti-leukemic effect of a novel histone deacetylase inhibitor MCT-1 and 5-aza-cytidine involves augmentation of Nur77 and inhibition of MMP-9 expression, International Journal of Oncology [P], vol 34, issue 2, Spandidos Publications, Greece, pp. 573-579.

Shehu-Xhilaga, M., Rhodes, D., Wightman, F., Liu, H.B., Solomon, A., Saleh, S.M., Dear, A.E., Cameron, P.U., Lewin, S.R., 2009, The novel histone deacetylase inhibitors metacept-1 and metacept-3 potently increase HIV-1 transcription in latently infected cells, AIDS [P], vol 23, issue 15, Lippincott Williams & Wilkins, United States, pp. 2047-2050.

Vinh, A., Gaspari, T.A., Liu, H., Dousha, L., Widdop, R.E., Dear, A.E., 2008, A novel histone deacetylase inhibitor reduces abdominal aortic aneurysm formation in angiotensin II-infused apolipoprotein E-deficient mice, Journal of Vascular Research, vol 45, Karger, Switzerland, pp. 143-152.

Newbold, A., Lindemann, R.K., Cluse, L.A., Whitecross, K.F., Dear, A.E., Johnstone, R.W., 2008, Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin, Molecular Cancer Therapeutics, vol 7, issue 5, American Association for Cancer Research, United States, pp. 1066-1079.

Liu, H., Hu, Y., Simpson, R.W., Dear, A.E., 2008, Glucagon-like peptide-1 attenuates tumour necrosis factor-alpha-mediated induction of plasmogen activator inhibitor-1 expression, Journal of Endocrinology, vol 196, issue 1, Society for Endocrinology, UK, pp. 57-65.

Golledge, J., Karan, M., Moran, C., Muller, J., Clancy, P., Dear, A.E., Norman, P., 2008, Reduced expansion rate of abdominal aortic aneurysms in patients with diabetes may be related to aberrant monocyte-matrix interactions, European Heart Journal, vol 29, issue 5, Oxford University Press, England, pp. 665-672.

Lindemann, R.K., Newbold, A., Whitecross, K.F., Cluse, L.A., Frew, A.J., Ellis, L., Williams, S., Wiegmans, A.P., Dear, A.E., Scott, C.L., Pellegrini, M., Wei, A., Richon, V.M., Marks, P.A., Lowe, s.w., Smyth, M.J., Johnstone, R.W., 2007, Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma, Proceedings of the National Academy of Sciences of the United States of America, vol 104, issue 19, National Academy of Sciences, USA, pp. 8071-8076.

Golledge, J., Muller, J., Shephard, N., Clancy, P., Smallwood, L., Moran, C., Dear, A.E., Palmer, L.J., Norman, P., 2007, Association between osteopontin and human abdominal aortic aneurysm, Arteriosclerosis Thrombosis and Vascular Biology, vol 27, issue 3, Lippincott Williams and Wilkins, USA, pp. 655-660.

Byron, K., Dear, A.E., 2007, Genotype and adverse drug reactions to warfarin, Medical Journal of Australia, vol 187, issue 1, Australasian Medical Publishing Co Ltd, Australia, pp. 61-62.

Dear, A.E., Liu, H.B., Mayes, P.A., Perlmutter, P., 2006, Conformational analogues of Oxamflatin as histone deacetylase inhibitors, Organic & Biomolecular Chemistry, vol 4, issue 20, Royal Society of Chemistry, UK, pp. 3778-3784.

Liu, H.B., Simpson, R.W., Dear, A.E., 2006, GLP-1 attenuates TNF-alpha-mediated induction of PAI-1 expression in vascular endothelial cells, Diabetes, vol 55, issue Supl 1, American Diabetes Association, USA, p. A343.

Liu, H.B., Hu, Y.S., Medcalf, R.L., Simpson, R.W., Dear, A.E., 2005, Thiazolidinediones inhibit TNFalpha induction of PAI-1 independent of PPARgamma activation, Biochemical and Biophysical Research Communications, vol 334, Academic Press, USA, pp. 30-37.

Cakarovski, K., Leung, J.Y., Restall, C., Carin-Carlson, A., Yang, E., Perlmutter, P., Anderson, R., Medcalf, R.L., Dear, A.E., 2004, Novel Inhibitors of Urokinase-type Plasminogen Activator and Matrix Metalloproteinase Expression in Metastatic Cancer Cell Lines, Internal Journal of Cancer, vol 110, issue 4, Wiley-Liss,Inc, USA, pp. 610-616.

Peart, M.J., Tainton, K.M., Ruefli, A.A., Dear, A.E., Sedelies, K.A., O'Reilly, L.A., Waterhouse, N.J., Trapani, J.A., Johnstone, R.W., 2003, Novel mechanisms of apoptosis induced by histone deacetylase inhibitors, Cancer Research, vol 63, issue 15, American Association for Cancer Research, Birmingham USA, pp. 4460-4471.

Dear, A.E., Medcalf, R.L., 2000, The novel anti-tumour agent oxamflatin differentially regulates urokinase and plasminogen activator inhibitor type 2 expression and inhibits urokinase-mediated proteolytic activity, Biochimica et Biophysica Acta, vol 1492, Elsevier Science BV, Amersterdam Netherland, pp. 15-22.

Dear, A.E., Medcalf, R.L., 1998, The urokinase-type-plasminogen-activator receptor (CD87) is a pleiotropic molecule, Eur. J. Biochem, vol 252, FEBS, Europe, pp. 185-193.

Dear, A.E., Costa, M., Medcalf, R.L., 1997, Urokinase-mediated transactivation of the plasminogen activator inhibitor type 2 (PAI-2) gene promoter in HT-1080 calles utilises AP-1 binding sites and potentiates phorbol ester-mediated induction of endogenous PAI-2 mRNA, FEBS Letters, vol 402, Elsevier Science, Amsterdam Netherlands, pp. 265-272.

Grants

Title:
ASPIRE: Aspirin to prevent recurrent venous thromboembolism.
Investigators:
Salem, H, Coughlin, P, Dear, A, Mapp, S
Funding:
(2004 - 2008). National Health & Medical Research Council (NHMRC).
Title:
Characterisation of a Novel Autoregulatory Mechanism Modulating the Progression of Atherosclerosis.
Investigators:
Medcalf, R, Dear, A
Funding:
(1999 - 2000). Heart Foundation of Australia.
(1999 - 2003). Heart Foundation of Australia.
Title:
Characterisation of potential therapeutic effects of DPP-IV inhibition in models of vascular endothelial cell dysfunction and atherosclerosis.
Investigators:
Simpson, R, Dear, A
Funding:
(2009 - 2013). Merck, Sharp & Dohme (Australia) Pty Ltd.
Title:
Characterization of the Effects of Liraglutide on Vascular Endothelial Peptide Expression.
Investigators:
Simpson, R, Dear, A
Funding:
(2006 - 2010). Novo Nordisk A/S.
Title:
Van Gogh DVT Trial: Comparing the efficacy & safety of once-weekly subcutaneous SanOrg34006 with the combination of (LMW) Heparin & vitamin K antagonist (VKA) in the treatment of acute symptomatic dee.
Investigators:
Salem, H, Coughlin, P, Mapp, S, Dear, A
Funding:
(2004 - 2008). Sanofi-Synthelabo.

Postgraduate Research Supervisions

Current Supervision

Program of Study:
(DOCTORATE BY RESEARCH).
Thesis Title:
The use of Histone Deacetlyase inhibitors to reverse HIV-1 latency.
Supervisors:
Lewin, S (Main), Dear, A (Associate).

Completed Supervision

Student:
Mayes, P.
Program of Study:
Towards a new steroid synthesis; conformational analogues of oxamflatin as histone deacetylase inhibitors. (PHD) 2007.
Supervisors:
Perlmutter, P (Main), Dear, A (Associate).
Student:
Vinh, A.
Program of Study:
Angiotensin IV-evoked modulation of vascular function and atherogenesis in ApoE-deficient mice. (PHD) 2008.
Supervisors:
Gaspari, T (Joint), Widdop, R (Joint-Co), Dear, A (Associate).